

Current Effective Date: 5/1/25

Status: Approved

Reviewed by Medical Policy Subcommittee: 5/1/25

Reviewed Dates: 3/21/25

---

#### **INSTRUCTIONS FOR USE DISCLAIMER:**

SummaCare posts policies relating to coverage and medical necessity issues to assist members and providers in administering member benefits. These policies do not constitute a contract or agreement between SummaCare and any member or provider. The policies are guidelines only and are intended to assist members and providers with coverage issues. SummaCare is not a health care provider, does not provide or assist with health care services or treatment, and does not make guarantees as to the effectiveness of treatment administered by providers. The treatment of members is the sole responsibility of the treating provider, who is not an employee of SummaCare, but is an independent contractor in private practice. The policies posted to this site may be updated and are subject to change without prior notice to members or providers.

Medical policies in conjunction with other nationally recognized standards of care are used to make medical coverage decisions.

---

### **Streptococcus Pneumoniae Antibody Testing Policy**

#### **Indication/Usage:**

*Streptococcus pneumoniae* is a gram-positive bacteria. A variety of infections can be caused by *Streptococcus pneumoniae* such as respiratory tract infections, including pneumonia and can lead to invasive disease, such as septicemia or meningitis. Healthy individuals will develop pneumococcal-specific antibodies, with the serotype after receiving the pneumococcal vaccine. Some individuals with immunodeficiencies may not demonstrate an adequate antibody response after vaccination. Measurement of antibodies against pneumococcal polysaccharides may be useful for diagnostic evaluation for suspected immunodeficiency.

## **Medical Indications for Authorization Commercial and Medicare Members**

SummaCare considers quantitative *Streptococcus pneumoniae* antibody (IgG) testing medically necessary to diagnose immunodeficiency syndromes in persons with recurrent bacterial infections and inadequate antibody response after receiving the pneumococcal polysaccharide vaccine, and to assess their eligibility for parenteral immunoglobulin replacement.

### **CPT code**

**86581:** *Streptococcus pneumoniae* antibody (IgG), serotypes, multiplex immunoassay, quantitative

There are currently no NCD or LCD for per CMS

### **Limitations**

SummaCare considers quantitative *Streptococcus pneumoniae* antibody testing experimental, investigational for all other indications because its clinical value has not been established.

### **Coverage Decisions**

Coverage decisions made per CMS, Hayes and industry standards research

### **Plans Covered By This Policy**

Commercial and Medicare

Self-funded Commercial groups refer to plan document for coverage

### **Sources Reviewed**

Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). ACIP recommendations. Atlanta, GA: CDC: Available at: <https://www.cdc.gov/vaccines/acip/recommendations.html>.

Centers for Disease Control and Prevention (CDC). Vaccines and preventable diseases: Pneumococcal vaccination: Summary of who and when to vaccinate. Atlanta, GA Available at: <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html>.

Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Updated recommendations for prevention of invasive pneumococcal disease among adults using

the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010; 59(34):1102-1106.

Orange JS, Hossny EM, Weiler CR, et al; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006; 117(4 Suppl):S525-5553.

Merck & Co., Inc. U.S. FDA approves Capvaxive (pneumococcal 21-valent conjugate vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Media News Release. Rahway, NJ: Merck; June 17, 2024c

Squires SG, Spika JS. Protecting against invasive pneumococcal disease: Be wise--immunize! CMAJ. 1998; 159(7):826-827.

CPT® Code 86581 - Qualitative or Semiquantitative Immunoassays - Codify by AAPC

Testing for Streptococcus pneumoniae Antibodies - Insights

CMS MCD Search

Hayes Knowledge Center | symplr